What they're not telling you: # Trump Says He's Not Replacing FDA Chief Makary President Trump denied reports that he plans to remove FDA Commissioner Marty Makary, telling reporters on May 8 that the embattled chief is "doing fine"—a seemingly casual dismissal of mounting pressure from prominent pro-life activists demanding his ouster. The denial came amid swirling speculation fueled by unnamed sources claiming the administration intended to fire Makary over his handling of mifepristone, the abortion drug at the center of an escalating regulatory battle. White House spokesman Kush Desai reinforced Trump's position with a statement asserting the administration has "assembled the most experienced and talented administration in history." Yet Trump notably provided no substantive defense of Makary's record or elaboration on why he remains confident in his FDA chief's performance—a notable gap given the intensity of the pressure campaign against him.
# THE TAKE: Trump's FDA Theater Doesn't Change the Script Trump claims Makary stays. Fine. But let's check the receipts. Makary—the Johns Hopkins surgeon who built his brand attacking "medical authoritarianism"—was always Trump's ideological fit. The real question isn't whether he's fired; it's whether he'll actually deregulate pharma or just *perform* it. Makary's track record? He co-authored op-eds dismissing lab-leak investigations, pushed hydroxychloroquine skepticism, then pivoted hard during Trump's comeback. That's not conviction—that's positioning. Trump keeping him signals one thing: no actual power transfer happening at FDA. Makary becomes the respectable face on deregulation theater while industry captures the agency through the back door. Not revolt. Colonization with better PR. The announcement itself is the distraction.
What the Documents Show
The controversy centers on a May 1 Fifth Circuit Court of Appeals ruling that blocked mifepristone from being mailed, citing the FDA's admitted failure to adequately study whether remote prescribing of the drug is safe. The decision directly implicated the agency's regulatory judgment under Makary's leadership. The Supreme Court subsequently put the ruling on hold following a request from Danco Laboratories, the pill's manufacturer. Mifepristone became available via mail and pharmacies in 2023 after federal authorities expanded access—a policy shift that has now become a flashpoint between competing political factions. Anthony Pro-Life America seized on the court ruling to escalate calls for Makary's removal, with President Marjorie Dannenfel declaring he should be "fired immediately" for alleged indifference to stricter abortion drug regulations.
Follow the Money
The organization framed Makary's continued tenure as a betrayal of pro-life voters' expectations. This pressure represents a specific ideological test case: whether Trump will prioritize the demands of his movement's most vocal constituencies even when doing so requires displacing officials his own administration has publicly backed. The mainstream framing of this story has centered on internal Trump administration drama and pro-life activist discontent. What receives less attention is what Makary's potential vulnerability reveals about the institutional independence of federal health agencies. Trump's May 8 statement that he knows "nothing about" removal plans, despite widespread reporting, suggests either a deliberate distance from the question or genuine disconnection from significant pressure campaigns targeting his appointees. Either scenario raises questions about how regulatory decisions at agencies like the FDA will be made going forward—whether based on scientific evidence, court rulings, or shifting political alignments.
What Else We Know
For ordinary Americans, the stakes involve access to medications that millions of women rely on. Whatever Trump's public position on Makary's tenure, the underlying battle over mifepristone regulation will ultimately determine whether women can obtain the drug remotely or only through in-person visits, and whether the FDA's decisions rest on safety data or political pressure.
Primary Sources
- Source: ZeroHedge
- Category: Government Secrets
- Cross-reference independently — don't take our word for it.
Disclosure: NewsAnarchist aggregates from public records, API feeds (Federal Register, CourtListener, MuckRock, Hacker News), and independent media. AI-assisted synthesis. Always verify primary sources linked above.